Research map: LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models

Back to the article

Papers in this map

  1. An Integrated Genomic Analysis of Human Glioblastoma Multiforme · Donald Williams Parsons · 2008 · 5914 citations · Cited by this paper
  2. Improving Knowledge and Care of Patients with AML: The Need to Get Out of Our Comfort Zone · 2026 · Related
  3. Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation · María E. Figueroa · 2010 · 2806 citations · Cited by this paper
  4. MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1 -Mutant Leukemia · 2026 · Related
  5. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome · Elaine R. Mardis · 2009 · 2248 citations · Cited by this paper
  6. Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry · 2026 · Related
  7. IDH mutation impairs histone demethylation and results in a block to cell differentiation · Chao Lü · 2012 · 2016 citations · Cited by this paper
  8. Rewiring the Leukemic Genome: 3D Chromatin Architecture in B-cell Acute Lymphoblastic Leukemia · 2026 · Related
  9. Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML · Courtney Denton Dinardo · 2018 · 1465 citations · Cited by this paper
  10. The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells · 2026 · Related
  11. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma · Ingo K. Mellinghoff · 2023 · 808 citations · Cited by this paper
  12. Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies · 2026 · Related
  13. IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication · Peter Paschka · 2010 · 806 citations · Cited by this paper
  14. Highlighted Research Articles · 2026 · Related
  15. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study · Guido Marcucci · 2010 · 772 citations · Cited by this paper
  16. Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma · 2026 · Related
  17. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate · Lenny Dang · 2010 · 617 citations · Cited by this paper
  18. Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial · 2026 · Related
  19. Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia · Pau Montesinos · 2022 · 517 citations · Cited by this paper
  20. A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma · 2026 · Related
  21. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations · Katharine E. Yen · 2017 · 474 citations · Cited by this paper
  22. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers · Janeta V. Popovici-Müller · 2018 · 456 citations · Cited by this paper
  23. The implications of IDH mutations for cancer development and therapy · Christopher J. Pirozzi · 2021 · 386 citations · Cited by this paper
  24. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response · Michael D. Amatangelo · 2017 · 367 citations · Cited by this paper
  25. Isocitrate dehydrogenase mutations in myeloid malignancies · Bruno C. Medeiros · 2016 · 350 citations · Cited by this paper
  26. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations · Andrew M. Intlekofer · 2018 · 290 citations · Cited by this paper
  27. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies · Annie Im · 2014 · 269 citations · Cited by this paper
  28. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition · James J. Harding · 2018 · 228 citations · Cited by this paper
  29. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer · Owen Clark · 2016 · 208 citations · Cited by this paper
  30. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML · Sung E. Choe · 2020 · 207 citations · Cited by this paper
  31. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib · Lynn Swun Quek · 2018 · 206 citations · Cited by this paper
  32. Isocitrate Dehydrogenase Mutation and ( R )-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development · Lenny Dang · 2017 · 204 citations · Cited by this paper
  33. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo · Janeta V. Popovici-Müller · 2012 · 202 citations · Cited by this paper
  34. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm · Ghayas C. Issa · 2021 · 200 citations · Cited by this paper
  35. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2 · Amir Tahmasb Fathi · 2018 · 199 citations · Cited by this paper
  36. Statistical determination of synergy based on Bliss definition of drugs independence · Eugene Demidenko · 2019 · 188 citations · Cited by this paper
  37. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations · Daniel A. Pollyea · 2022 · 171 citations · Cited by this paper
  38. Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor · Justin A. Caravella · 2020 · 151 citations · Cited by this paper
  39. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML · Stéphane de Botton · 2023 · 134 citations · Cited by this paper

Source: OpenAlex (CC0)